Search results

Found 150 pages
AUTHOR: PharmaTimes Reporter

Results per page

10 20 50 100

Sort by

Relevance Date

13 Feb 2013:

Amgen and UCB abandon fracture-healing drug trials

Amgen and Belgian partner UCB have abandoned efforts to develop romosozumab for fracture healing, although trials in post-menopausal osteoporosis will continue. - News - PharmaTimes

by PharmaTimes Reporter

https://www.pharmatimes.com/news/amgen_and_ucb_abandon_fracture-healing_drug_trials_1004429

25 Sep 2014:

Regulatory compliance is main pain in supply chain

An environment of “increasing risks, complex regulations and continuing cost pressures” is stopping healthcare executives from moving quickly to seize “untapped industry opportunities” in the supply chain, accord

by PharmaTimes reporter

https://www.pharmatimes.com/news/regulatory_compliance_is_main_pain_in_supply_chain_1002534

12 Feb 2013:

Bayer files PAH drug riociguat in US, EU

Bayer has launched an offensive on the pulmonary arterial hypertension (PAH) market, filing its riociguat drug candidate for approval in the US and EU. - News - PharmaTimes

by PharmaTimes Reporter

https://www.pharmatimes.com/news/bayer_files_pah_drug_riociguat_in_us,_eu_1004419

20 Dec 2013:

Bayer raises offer for Xofigo partner Algeta

Bayer has won over Algeta's board with a sweetened acquisition offer that values the Norwegian drugmaker at $2.9 billion. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/bayer_raises_offer_for_xofigo_partner_algeta_1006213

29 Oct 2013:

Januvia frailty holds back Merck in Q3

Merck & Co saw revenues slip 4 per cent in the third quarter as diabetes blockbuster Januvia continued to show signs of weakness in the US. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/januvia_frailty_holds_back_merck_in_q3_1005923

30 May 2013:

GSK strengthens vaccines business with Okairos buy

GlaxoSmithKline has purchased the Swiss-based vaccine technology company Okairos for 250 million euros in a deal that will bolster the firm’s biologics division. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/gsk_strengthens_vaccines_business_with_okairos_buy_1005106

17 Jun 2013:

AstraZeneca teams up with charity on cancer

Cancer Research UK, the University of Manchester and AstraZeneca have signed two new deals on developing cancer drugs. - News - PharmaTimes

by PharmaTimes Reporter

https://www.pharmatimes.com/news/astrazeneca_teams_up_with_charity_on_cancer_1005208

25 Mar 2014:

Afinitor/Aromasin combo disappoints in breast cancer trial

A combination of Novartis' Afinitor and Pfizer's Aromasin failed to reach statistical significance in a trial’s secondary endpoint of overall survival. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/afinitoraromasin_combo_disappoints_in_breast_cancer_trial_1001715

16 Aug 2013:

Amgen bid for Onyx 'sticking on Kyprolis data'

Amgen's proposed takeover of Onyx Pharmaceuticals is all but agreed, but is being held up by a dispute over access to data from a trial of multiple myeloma treatment Kyprolis, according to Bloomberg. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/amgen_bid_for_onyx_sticking_on_kyprolis_data_1005553

19 Aug 2013:

Lilly starts defense of Alimta patent in US

Eli Lilly is due to start the defense of its blockbuster lung cancer therapy Alimta in a US district court later today in a bid to keep exclusivity for the product until 2022. - News - PharmaTimes

by PharmaTimes reporter

https://www.pharmatimes.com/news/lilly_starts_defense_of_alimta_patent_in_us_1005559